6I83

Crystal structure of phosphorylated RET V804M tyrosine kinase domain complexed with PDD00018366

6I83 の概要

• エントリーDOI: 10.2210/pdb6i83/pdb
• 関連するPDBエントリー: 6I82
• 分子名称: Proto-oncogene tyrosine-protein kinase receptor Ret, 4-[5-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]benzamide, FORMIC ACID, ... (4 entities in total)
• 機能のキーワード: inhibitor, kinase, proto-oncogene, oncoprotein
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 36855.02

構造登録者

Burschowsky, D.,Seewooruthun, C.,Bayliss, R.,Carr, M.D.,Echalier, A.,Jordan, A.M. (登録日: 2018-11-19, 公開日: 2020-03-11, 最終更新日: 2024-11-13)

主引用文献

Newton, R.,Waszkowycz, B.,Seewooruthun, C.,Burschowsky, D.,Richards, M.,Hitchin, S.,Begum, H.,Watson, A.,French, E.,Hamilton, N.,Jones, S.,Lin, L.Y.,Waddell, I.,Echalier, A.,Bayliss, R.,Jordan, A.M.,Ogilvie, D.
Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RETV804MKinase.
Acs Med.Chem.Lett., 11:497-505, 2020

PubMed Abstract: A combination of focused library and virtual screening, hit expansion, and rational design has resulted in the development of a series of inhibitors of RET kinase, the anticipated drug-resistant mutant of RET kinase. These agents do not inhibit the wild type (wt) isoforms of RET or KDR and therefore offer a potential adjunct to RET inhibitors currently undergoing clinical evaluation.

PubMed: 32292556
DOI: 10.1021/acsmedchemlett.9b00615

実験手法

X-RAY DIFFRACTION (1.88 Å)